产经

订阅

MedSci主页 / 所有栏目 / 产经

恒瑞与孙飘扬共同出资1亿元设立新公司：专注研发抗病毒药物

2020-07-07 网络 网络

恒瑞医药
关注

恒瑞医药6日晚公告，公司全资子公司上海恒瑞，拟与公司实控人孙飘扬共同出资设立瑞利迪（上海）生物医药有限公司，由瑞利迪负责抗病毒疗法的研发、生产、销售及相关的进出口业务。瑞利迪的注册资本为1亿元，其中，

恒瑞医药6日晚公告，公司全资子公司上海恒瑞，拟与公司实控人孙飘扬共同出资设立瑞利迪（上海）生物医药有限公司，由瑞利迪负责抗病毒疗法的研发、生产、销售及相关的进出口业务。瑞利迪的注册资本为1亿元，其中，上海恒瑞认缴出资6000万元，占注册资本的60%；孙飘扬认缴出资4000万元，占注册资本的40%。抗病毒药物是公司新涉足的领域，本次交易有利于公司丰富产品线，是公司发展战略的重要一环。

 



 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1292526, encodeId=de0d129252646, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Jul 09 14:42:06 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300407, encodeId=778d130040e2a, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Jul 09 14:42:06 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363362, encodeId=3e1e13633623c, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Thu Jul 09 14:42:06 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801675, encodeId=9e988016e5bb, content=什么逻辑？, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 08 00:05:29 CST 2020, time=2020-07-08, status=1, ipAttribution=)]
    2020-07-09 yahu

    #抗病毒#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1292526, encodeId=de0d129252646, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Jul 09 14:42:06 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300407, encodeId=778d130040e2a, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Jul 09 14:42:06 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363362, encodeId=3e1e13633623c, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Thu Jul 09 14:42:06 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801675, encodeId=9e988016e5bb, content=什么逻辑？, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 08 00:05:29 CST 2020, time=2020-07-08, status=1, ipAttribution=)]
    2020-07-09 lqvr

    #研发#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1292526, encodeId=de0d129252646, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Jul 09 14:42:06 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300407, encodeId=778d130040e2a, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Jul 09 14:42:06 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363362, encodeId=3e1e13633623c, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Thu Jul 09 14:42:06 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801675, encodeId=9e988016e5bb, content=什么逻辑？, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 08 00:05:29 CST 2020, time=2020-07-08, status=1, ipAttribution=)]
    2020-07-09 yangshch

    #抗病毒药物#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1292526, encodeId=de0d129252646, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Jul 09 14:42:06 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300407, encodeId=778d130040e2a, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Jul 09 14:42:06 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363362, encodeId=3e1e13633623c, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Thu Jul 09 14:42:06 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801675, encodeId=9e988016e5bb, content=什么逻辑？, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 08 00:05:29 CST 2020, time=2020-07-08, status=1, ipAttribution=)]
    2020-07-08 lovetcm

    什么逻辑？

    0

相关资讯

年赚均超10亿 看这16家制药公司怎么花钱

2016年， A股（含A股、港股共同上市）有16家上市药企净利润超10亿元。作为最会赚钱的企业，这几家公司的花钱之道也颇值得探讨。新康界统计发现，受市场推广费增加等因素影响，这些公司的销售费用都在持续增加，有6家公司同比增长超20%，其中费用最高的是68.50亿元的步长制药。与此同时，在自主创新的大趋势下，其研发投入也普遍有较大的增长：有8家公司的研发投入同比增长超20%，其中6家为化学药，恒瑞医

昂贵国产PD-1慈善赠药政策公布

近日，恒瑞医药的PD-1抑制剂卡瑞利珠单抗慈善赠药政策正式公布。

医药上市公司去年研发花了多少钱？ 恒瑞医药近12亿当上创新领头羊

37家医药上市公司中，有12家研发费用总额达到亿元级别。